there are only 67 trials included in the analysis. Also, my interpretation of the finding on page 9, line 23 -26 is that the authors found systematic reviews or RCTs that were relevant to the intervention in all protocols that they investigated; however, only 59 reported these studies in their protocol, whereas 8 did not. However, in the discussion, the authors state that for 72% of protocols, evidence of systematic reviews or RCTs on the particular intervention under investigation did not exist in the literature, contrary to what was reported in the findings. Were the 72% of RCT's the first RCT's to be conducted on a particular intervention? If so, then there wouldn't be supporting evidence from past RCT's to justify the conduct of the trial and the others potentially need to explore and take into consideration other types of research designs to justify the conduct of an RCT. The authors need to make their findings more clear.
Minor
Introduction (Page 5) 4. The authors need to include information about the SPIRIT statement as it is an important development in this area. 5. Line 24 -the authors should make clear that the "results of previous similar trials" include both positive and negative results. Methods 1. Page 5, line 40 -Please include the dates over which research projects were screened 2. Page 5, line 12 -The authors should spell out the sub-title 'inclusion' in full. 3. Page 5, line 37 -please remove the common after "harm,." 4. Page 6, Data extractionperhaps the use of sub headings in italics of the different areas of assessment to make this section easier to follow. E.g. Funder, Justification of comparators etc. 5. Page 6, line 25 -Please describe what the comparator "nothing" is. Does this mean waitlist or treatment as usual? 6. Page 6 -To ensure this section flows more smoothly, paragraph 6 needs to be moved above paragraph 5 and some paragraphs need to be joined together; e.g. seven and eight. 7. Page 6, paragraph 7 (line 41)please refer the reader to the "Searches for relevant trials" section for the search strategy used to identify systematic reviews and other relevant trials. 8. Page 6, line 43 -The authors need to describe how they are going to use a qualitative assessment and provide examples of 'texts of interest' they used to facilitate their qualitative assessment. 9. Page 6, line 53 -Did the authors assess whether protocols included evidence about both the benefits and harms of the intervention they were investigating? 10. Page 7, line 13 -Please switch 'inguinal hernia' with 'mesh' to adhere to the example given above. 11. Page 7, line 20 -The authors need to make clear that from their literature search, they excluded trials that weren't RCT's. It would also be important to justify why they did this. 12. Page 7, Line 22-24 -This paragraph should be cut and pasted into the "Data Extraction" section of the Methods. Results 13. Page 7, line 36 -It would be useful for the reader if the others could include a referral to Figure 1 at the end of this paragraph. 14. Page 8, line 20 -The authors need to define what "no treatment" means. Is it a waitlist or treatment as usual? Please clarify.
15. Page 8, line 27 -Please explain what is meant by "explicit" and "implicit" justification. 16. Page 8, line 30 -Please briefly describe the criteria on which the studies are not ethically justified, rather than referring the reader to the methods section. 17. Page 9, line 5 -Consider changing the 'second protocol' to the 'other protocol' to avoid confusion. 18. Page 9join paragraph two and three together. 19. The authors should consider detailing the types of intervention (e.g. medical, surgical, psychological, psychiatric) that are being investigated in the protocols and for what condition they aim to treat (E.g. anxiety) so that the readers can observe the relevance of their findings to their discipline. Discussion 20. Page 9, line 26 -The finding at the end of this paragraph is not reported in the results section and is contrary to what is found in the results section. Please clarify. 21. Page 10, line 20 -"the earlier sample"is this related to the 2016 study? Please make this clear. 22. Page 10, line 44 -The authors mention that they have "not considered unpublished trials" however do not mention in their methods that they only looked at protocols that had already published their results. I thought the authors investigated protocols of all registered clinical trials (between 2012-2013) regardless of whether or not the findings had been published. If the authors did only look at registered trials that were also published, they would need to include this an as a criteria of inclusion.
REVIEWER
David Henry Bond University, Gold Coast, Queensland, Australia REVIEW RETURNED 02-Nov-2018
GENERAL COMMENTS
Authors' objective: To investigate to what extent contemporary protocols for randomised clinical trials search for and use previous similar studies or systematic reviews to justify conducting new trials.
I think this is an important topic and the authors are justified in pursuing it. The title and the objectives are appropriately concerned with the adequacy of literature searching during the planning of clinical trials. And I agree with the authors that the topic has ethical implications.
My principal concern is that the manuscript drifts from this to a consideration of other ethical issues, which become front and centre. While I agree that the related issues of choice of comparator and justification of overall trial rationale is important, these aspects of the paper do not have a clear and adequate underlying methodology. Judgments are complex and difficult and are affected by evidence, contemporaneous interpretation of evidence, and contextfor instance what decisions are being made (e.g. licensing versus coverage of a drug or procedure). I think the methods the authors have used for this part of the work are weak and the results have been over-interpreted. For that reason, I recommend that this section of the manuscript is removed.
1. In selecting studies the authors state: "We excluded trials with only surrogate primary outcomes (e.g. cholesterol levels), as these tend to overestimate the benefit of drugs and overlook serious harms". This statement is supported by a self-citation from 1996. 2. In relation to ethical judgments the authors state "we judged whether the trial described in a protocol was ethically justified. When making this judgement we considered whether the protocol established a scientific need for the trial in question." On what criteria did they make that judgment? I feel that a minimum scientific standard would involve the elaboration of criteria and a judgment made by individuals with some content expertise who were blind to the trial sponsorship details.
3. The authors judged whether the "choice of comparator and outcomes was appropriate based on the literature available at the time. We defined a comparator as unethical if another intervention had already been proven more effective for the outcomes measured and no compelling reason for using an inferior comparator was provided." How did they judge comparative effectiveness? As with item 3, these are complex judgments and require assurance of contemporaneity, clinical and statistical superiority (or non-inferiority) and should be made by a group that includes individuals with content knowledge and who are blind to sponsorship details. Perhaps the authors did this, but I cannot find the information in their Methods section. 4. The authors state "When assessing the scientific rationale for a study, we judged whether the protocol provided evidence that there was genuine equipoise to justify an RCT and whether choice of outcomes and methodology was appropriate for the scientific question posed." As with my items 3 and 4 the judgments are complex, and the authors don't describe a rigorous methodology.
5.
In the Results the authors state "We found that 11 studies (16%) were not ethically justified, based on the criteria described in the methods section. The reasons for these judgements are described in Box 1". Accusing trialists of undertaking trials that were not ethically justified is a big call and as noted earlier I didn't feel that adequate and transparent scientific rigor was used to make these judgments. The authors acknowledge (Discussion) that the judgments are subjective. In the attachment I have gone through the judgements in Box 1 of the paper and annotated each with a comment. I appreciate that the authors made an undertaking not to reveal identity of trials and therefore are constrained in the detail they provide. I am not claiming my comments are correct and their judgements are wrong; rather that it is not possible to tell. And with weak methodology and sparse information I can produce a superficially credible rebuttal for each judgment about lack of ethics that they include in Box 1.
6. In contrast I am comfortable with the results relating to literature searching in trial protocols as this is less subjective and less prone to misclassification. However, one point of clarification should be made. If trials involved new medications or devices at an early stage of their development there may not be a substantial publication history and the relevant information may sit in sponsors' files. It's unlikely anyone will have done systematic reviews. I don't know how relevant it is here, but the authors might comment.
7. In the Discussion the authors have again taken a very polar view of the ethics of rationales for trials. They cite two examplesa cumulative meta-analysis of streptokinase in AMI showing that after 1973 there was compelling evidence of benefit. I am not sure what point they are making but it is unreasonable to suggest that all thrombolytic trials post 1973 were 'unethical'. Ethical standards evolve with new knowledge and retrospective application of a 2018 standard is simply unfair and biased. In the case of their other example, aprotinin, the situation is much more complicated than they state. I have performed a systematic review of this literature. Small inadequately powered trials were done over a long period in different settingscardiac surgery, general surgery, orthopedic surgery, children etc. The difficulty with all these trials is that although they continued to show a reduction in blood loss (and sometimes need for reoperation) they were inconclusive about other major clinical outcomes. Eventually the authors of the systematic review cited in this manuscript performed a large RCT which showed an increase in mortality with aprotinin compared with lysine analogues. So, to claim it was unethical to do further trials at an earlier stage is misleading and what was needed was a proper trial. My point here, again, is that these issues are not black and white.
8. Finally, I support the authors' call for much more detailed literature reviews during the planning of trialsa point made by othersand I agree with their call for ethics review organisations to be fully transparent in their work as they are working in the public interest.
Other Points 9. To start with Methods: The authors state "Our previous research on Danish trial protocols indicated that a sample size of 60 protocols would be sufficient to answer our research questions." I don't understand the scientific basis of this statement. As most of the paper is descriptive and concerned with proportions it would be usual to estimate the power of the study to detect certain proportions with a specified precision; alternatively, make no mention of sample size and provide confidence intervals for key statistics.
10. The authors have used the SPIRIT guidelines to assess the appropriateness of choice of comparators (controls). They reference the Statement itself, rather than the explanation and elaboration paper, published in the BMJ. I think the latter is more appropriate as it has a section on selection of comparators, which is useful but far from comprehensive and doesn't provide a framework that would cover the broad range of interventions used here (see below).
11. Protocols were selected between October 2012 through March 2013 was that 1st to 31st? Actual dates should be provided.
They state "
We sought additional information about the research projects through clinicaltrials.gov, and the World Health Organisation International Clinical Trial Registry Platform. If we were unable to find a study in trial registries, we supplemented with a Google search." I can understand the information in registries but what were they looking for in a Google search? What terms did they search onwere they looking for the protocol or a subsequent publication of the trial?
13. Why were decisions made by only one observer? There are six named authors. Which of the authors extracted the information? Given the subjective nature of some steps why was this not done in duplicate?
14. "For the trials that might be eligible". I understand the main eligibility criteria, but what criteria were used by the single observer at this screening stage?
VERSION 1 -AUTHOR RESPONSE
Comments from Reviewer 1 Major 1. The authors have spent several years trying to gain access to some trial protocols, which in some cases has involved consultation with lawyers. Unfortunately, this means that the findings are over five years old and therefore may not be relevant today. A more recent study (Pandis et al, 2016) has conducted a similar investigation finding that protocols in 2015 were of a better quality. The paper would be significantly strengthened if the authors repeated the investigation over the past year (2017-2018) and compared the current findings to those from 2012-2013.
-We agree that this is a limitation of our study and it was only briefly mentioned in the "Strengths and Limitations" section of the discussion. We have added the following (page 11, line 28-31):
"Our included protocols are over five years old but as systematic literature searches are still not mandatory for approval of protocols in Denmark, our results are likely valid today. Ethics committees in Denmark now have access to the Investigators' Brochure which might contain some of the information we looked for but did not find."
While we agree that it would be very interesting to compare our results with a more current sample, this is not feasible. Getting access to the protocols, identification of relevant studies, retrieval of those studies and data extraction were all very labour intensive and time consuming and repeating this process would constitute an entirely new research project. We would likely end up with a similar delay if we followed the reviewer's suggestion.
We would also like to point out that obtaining a sample from 2017 to 2018 would exclude the possibility to compare protocols with published papers, which was also an objective, although it was not part of this specific paper.
Regarding Pandis et al., there are some important differences between their study and ours. As we point out in our Discussion, Pandis et al. assessed whether any randomized trial or systematic review was cited whereas we also looked at whether any trial or review that was cited had direct relevance to the intervention and population described in the protocol. Additionally, Pandis et al. only looked at published protocols whereas our sample was from ethics committees.
2. The SPIRIT statement is an important development to improve the quality of clinical trial protocols. The authors have used the SPIRIT guidelines to assess a trials choice of comparator (Page 6, line 24); however, it is unclear whether they also used these guidelines to assess other elements such as the trials rationale (identifying relevant research, including benefits and harms). The authors should report the extent to which the protocols they assessed adhered to the SPIRIT guidelines.
-We agree that the SPIRIT guidelines are a useful tool when considering quality of clinical trial protocols. Indeed, we have collaborated for many years with several of the authors behind the SPIRIT statement. Point 6 in the SPIRIT Statement deal with the rationale of a trial and we used this as a basis for judging the rationale of the trials described in the protocols included in our sample.
We have rephrased and clarified the section about trial rationale, so it reflects how we applied the points made in the SPIRIT statement about the rationale for the trial.
See our response to minor point 8 from reviewer 1 3. The results (Page 8, 'Comparators and ethical justification', paragraph 1 are quite confusing and do not seem to compute. The number of trials that have used placebo, active comparator or waitlist/treatment as usual equates to a total of 74 trials; however, there are only 67 trials included in the analysis. Also, my interpretation of the finding on page 9, line 23 -26 is that the authors found systematic reviews or RCTs that were relevant to the intervention in all protocols that they investigated; however, only 59 reported these studies in their protocol, whereas 8 did not. However, in the discussion, the authors state that for 72% of protocols, evidence of systematic reviews or RCTs on the particular intervention under investigation did not exist in the literature, contrary to what was reported in the findings. Were the 72% of RCT's the first RCT's to be conducted on a particular intervention? If so, then there wouldn't be supporting evidence from past RCT's to justify the conduct of the trial and the others potentially need to explore and take into consideration other types of research designs to justify the conduct of an RCT. The authors need to make their findings more clear.
We have clarified the reporting of our results.
Regarding the section about types of comparators, the numbers do not add up to 67 as some trials had multiple arms with different comparators. We have tried to make this clearer (page 9, line 15-18):
"Placebo was the only comparator in 18 (27%) of the trials. Thirty-two trials (48%) used active comparators only and 10 trials (15%) used no treatment as the only comparator. Six trials (9%) used both a placebo-arm and an arm with an active comparator. One trial (1%) used both an active comparator arm and an arm with no treatment."
Regarding the finding on page 9, line 23, we have not been sufficiently clear, and we have changed the section and added a table. The section now reads (page 10, line 4-14):
"Twelve protocols (18%) cited either a systematic review or a randomised trial with clear, direct relevance for the intervention, population and/or indication studied. Two protocols (3%) cited one or more systematic reviews, eight protocols (12%) cited one or more randomised trial and two protocols (3%) cited both systematic reviews and randomised trials. For 11 of these 12 protocols (92%), we did not find additional relevant trials through our own systematic search. For the remaining one protocol (8%) we identified one systematic review and two randomised trials (819 included trial participants) that could have been relevant to cite.
The remaining 55 protocols (82%) cited no relevant systematic reviews or randomised trials. However, for 48 of these 55 protocols (87%) we did not identify any studies that could have been cited. For the remaining seven protocols (13%) we identified 10 randomised trials and one systematic review (with a total of 2080 included trial participants) that could have been cited. These results are summarised in Table 3 ."
Minor Introduction (Page 5)
4.
The authors need to include information about the SPIRIT statement as it is an important development in this area.
We have added the following (page 5, line 10-13):
"In 2013 the SPIRIT Statement was published. It outlines 33 items (with subitems) that should be adequately reported in clinical trial protocols. Item 6 is "Background and Rationale" which describes the importance of justifying a new trial in the context of the available evidence. It is "strongly recommended that an up-to-date systematic review of relevant studies be summarised and cited in the protocol".4" 5. Line 24 -the authors should make clear that the "results of previous similar trials" include both positive and negative results.
We have added the following: "whether positive or negative" Methods 1.
Page 5, line 40 -Please include the dates over which research projects were screened
We added the following:
"Between October 2013 and February 2014" 2. Page 5, line 12 -The authors should spell out the sub-title 'inclusion' in full.
Done

3.
Page 5, line 37 -please remove the common after "harm,." Done 4. Page 6, Data extractionperhaps the use of sub headings in italics of the different areas of assessment to make this section easier to follow. E.g. Funder, Justification of comparators etc.
Thank you for this suggestion, we have done that.
5.
Page 6, line 25 -Please describe what the comparator "nothing" is. Does this mean waitlist or treatment as usual?
We changed the paragraph to (page 6, line 36 to page 7, line 5):
"The type of comparator used in the control arm was classified as either an active comparator, placebo, or 'nothing'. In trials that used a comparator classified as 'nothing' participants received either no treatment or were put on a waiting list. Trials with more than two arms could use more than one type of comparator; in this case we classified a trial as using a combination of the above, e.g. a trial could be classified as having a placebo arm as well as an active comparator arm. Comparators described in the protocol as 'usual/standard care could be either 'active treatment' or 'no treatment' and was classified according to the description in the protocol."
6.
Page 6 -To ensure this section flows more smoothly, paragraph 6 needs to be moved above paragraph 5 and some paragraphs need to be joined together; e.g. seven and eight.
Done
7.
Page 6, paragraph 7 (line 41) -please refer the reader to the "Searches for relevant trials" section for the search strategy used to identify systematic reviews and other relevant trials.
"We compared the references in the protocols with the results of our own systematic searches (See Searches for relevant trials)."
8.
Page 6, line 43 -The authors need to describe how they are going to use a qualitative assessment and provide examples of 'texts of interest' they used to facilitate their qualitative assessment.
We acknowledge that the subjective nature of our judgements makes it especially important to report our methods adequately and thank the reviewer for this comment. We have changed the whole section to the following (page 7, line 21 to page 8, line 5):
"We read the included protocols in full and checked their references to identify trials of similar interventions, for similar indications, and in similar populations. We also checked all references in any systematic reviews that were cited in the protocol to see if these identified relevant trials. When we checked the existing trials and systematic reviews, we looked for both evidence on benefits and harms. We compared the references in the protocols with the results of a systematic search we performed ourselves (see below: Searches for relevant trials). We defined a comparator as potentially unjustified if another intervention had already been proven more effective for the outcomes measured and no compelling reason for using another comparator was provided. When judging comparative efficacy, we only considered direct evidence, i.e. we only judged a comparator potentially unjustified if another intervention had been directly tested against the comparator for the same (or a similar) indication and found superior.
When assessing the scientific rationale for a study, we judged whether the protocol provided evidence that there was clinical equipoise to justify an RCT. This judgement was based on the principles outlined in item 6A of the SPIRIT statement4 and in the SPIRIT explanation and elaboration paper10 where it is explained that a protocol should "summarise the importance of the research question, justify the need of the trial in the context of available evidence, and present any available data regarding the potential effects of the interventions (benefits and harms)".4,10 Thus, we examined whether a protocol either identified a lack of studies of direct relevance or established that results of previous studies were inconclusive, and whether the choice of outcomes and methodology was appropriate for the scientific question posed. We did not judge the soundness of the scientific rationale for the trials as this would require content expertise, rather we judged whether a scientific rationale was provided and whether it was backed by references to systematic reviews or randomised trials."
9.
Page 6, line 53 -Did the authors assess whether protocols included evidence about both the benefits and harms of the intervention they were investigating?
We did and have now explained this in the text (page 7, line 23-24):
"When we checked existing trials and systematic reviews, we looked for both evidence on benefits and harms."
10.
Page 7, line 13 -Please switch 'inguinal hernia' with 'mesh' to adhere to the example given above.
Thank you for noticing this mistake. We switched the order in the example instead, as we find it more meaningful to start with the indication, and then the intervention.
11.
Page 7, line 20 -The authors need to make clear that from their literature search, they excluded trials that weren't RCT's. It would also be important to justify why they did this.
We have changed the paragraphs to the following (page 8, line 7-17):
"For each protocol, we conducted systematic searches to identify additional randomised trials or systematic reviews that could have been relevant to cite in the protocols. We restricted the study design to randomised trials when searching and we used simple and broad search strategies that could have been performed by researchers without experience with systematic literature searches. We searched PubMed and EMBASE and the search strings followed a general template:
[Indication] AND [Intervention] For example, the following search string was used for a study of the use of surgical mesh in inguinal hernia operations: inguinal hernia AND mesh AND fixation.
All searches were restricted to publications entered into the databases at least one month before the first submission of the protocol to the research ethics committee. We screened titles and abstracts from our searches and potentially eligible trials were read in full text to assess their relevance."
We acknowledge that randomised trials have limitations regarding rare harms and have added the following in the "strengths and limitations"-section of the discussion (page 12, line 5-7):
"Finally, we did not search for observational studies, although they can be important for detecting rare or unexpected harms. It is therefore possible that we would have found additional interventions or comparators to be problematic."
12.
Page 7, Line 22-24 -This paragraph should be cut and pasted into the "Data Extraction" section of the Methods.
Done
Results
12.
Page 7, line 36 -It would be useful for the reader if the others could include a referral to Figure 1 at the end of this paragraph.
Done
13.
Page 8, line 20 -The authors need to define what "no treatment" means. Is it a waitlist or treatment as usual? Please clarify.
Done, see above.
14.
Page 8, line 27 -Please explain what is meant by "explicit" and "implicit" justification.
We added the following to the methods section (page 7, line 9-15):
"We defined that a protocol explicitly justified the choice of comparator when a specific reason for the choice was given, e.g. a section such as "Rationale for choice of comparator" or statements such as "Regarding justification of placebo: "Placebo is the appropriate comparator, since the approved therapies available in same countries are not routinely used for treatment of lower-risk disease.""
The justification for choice of comparator was considered implicit when for example the control group was stated to simply receive the usual standard of care or when there was documented uncertainty about which of two active interventions was superior."
16.
Page 8, line 30 -Please briefly describe the criteria on which the studies are not ethically justified, rather than referring the reader to the methods section.
We changed the paragraph to the following (page 9, line 24-25):
"We identified 11 protocols (16%) where the choice of treatment or comparator could be questioned given the evidence available at the time. The reasons for these judgements are described in Box 1."
17.
Page 9, line 5 -Consider changing the 'second protocol' to the 'other protocol' to avoid confusion.
Thank you for this suggestion, done.
18.
Page 9join paragraph two and three together.
Done
19.
The authors should consider detailing the types of intervention (e.g. medical, surgical, psychological, psychiatric) that are being investigated in the protocols and for what condition they aim to treat (E.g. anxiety) so that the readers can observe the relevance of their findings to their discipline.
We agree that such a detailing would be interesting, and we have added a table describing the relevant medical specialties.
We have also added the following (page 9, line 12-13):
"Nineteen protocols (28%) described trials in oncology and 10 protocols (15%) surgical interventions. The specialities of the remaining 38 protocols can be seen in Table 2 ." Discussion 20.
Page 9, line 26 -The finding at the end of this paragraph is not reported in the results section and is contrary to what is found in the results section. Please clarify.
Done, see our answer to Major comment 3.
21.
Page 10, line 20 -"the earlier sample"is this related to the 2016 study? Please make this clear.
Thank you for pointing this out, we have changed the sentence to:
"Additionally, the 2016 study included only published protocols."
22.
Page 10, line 44 -The authors mention that they have "not considered unpublished trials" however do not mention in their methods that they only looked at protocols that had already published their results. I thought the authors investigated protocols of all registered clinical trials (between 2012-2013) regardless of whether or not the findings had been published. If the authors did only look at registered trials that were also published, they would need to include this an as a criteria of inclusion.
Thank you for this comment. The reviewer's understanding of our inclusion criteria is indeed correct. When we mention that we did not consider unpublished trials, we are referring to trials that could be identified through our own search. We have now clarified that we did not search for unpublished trials (page 12, line 1-4):
"We did not search for unpublished trials in our own systematic searches. Publication bias is a significant problem in medical research19, and trials with positive results are more likely to be published. Thus, there could be relevant studies that we did not identify. However, expecting protocol authors to find these may be unreasonable."
Comments from Reviewer 2
Major Issues
1.
In selecting studies the authors state: "We excluded trials with only surrogate primary outcomes (e.g. cholesterol levels), as these tend to overestimate the benefit of drugs and overlook serious harms". This statement is supported by a self-citation from 1996. They do not cite a large literature on the strengths and limitations of surrogate endpoints and the general limitations of RCTs in quantifying harms. Surrogate-endpoint studies don't 'overestimate' benefits. They measure a surrogate that may, or may not, enable accurate modelling of the impact on clinically relevant endpoints. Most surrogate-endpoint trials don't 'overlook' harmsthey are usually unable to quantify them. I think the language used to describe their limitations borders on pejorative and should be scientific and neutral. That said, I am not convinced that the authors should have excluded surrogateendpoint trials. They may not approve of them, but the ethical relevance of inadequate preparatory literature searches is a concern.
We agree and have changed the paragraph to the following (page 5, line 32-33):
"We excluded trials with only surrogate outcomes as determining the relevance of such outcomes to patients require detailed content area knowledge from diverse fields."
2.
In relation to ethical judgments the authors state "we judged whether the trial described in a protocol was ethically justified. When making this judgement we considered whether the protocol established a scientific need for the trial in question." On what criteria did they make that judgment? I feel that a minimum scientific standard would involve the elaboration of criteria and a judgment made by individuals with some content expertise who were blind to the trial sponsorship details.
We have clarified that we did not judge whether the trial was in fact ethically justified and agree that this would often require content expertise. We judged whether a scientific rationale was provided, not whether this rationale was scientifically sound, only if it was there and whether it was backed by references to existing trials or systematic reviews. See our response to minor comment 8 from reviewer 1.
3.
The authors judged whether the "choice of comparator and outcomes was appropriate based on the literature available at the time. We defined a comparator as unethical if another intervention had already been proven more effective for the outcomes measured and no compelling reason for using an inferior comparator was provided." How did they judge comparative effectiveness? As with item 3, these are complex judgments and require assurance of contemporaneity, clinical and statistical superiority (or non-inferiority) and should be made by a group that includes individuals with content knowledge and who are blind to sponsorship details. Perhaps the authors did this, but I cannot find the information in their Methods section.
The requirements set by the reviewer (involvement of content area expertise to judge the etichal justification of the comparator) would be beyond what many research ethics committees live up to. If an established treatment exists and is backed by randomised trials, it does not seem problematic to question the use of a placebo arm in a new trial. However, we agree that we should rephrase our text to more clearly express that we find the ethical justification questionable rather than giving the impression that we provide a definitive judgement.
See our response to minor comment 8 from reviewer 1.
4.
The authors state "When assessing the scientific rationale for a study, we judged whether the protocol provided evidence that there was genuine equipoise to justify an RCT and whether choice of outcomes and methodology was appropriate for the scientific question posed." As with my items 3 and 4 the judgments are complex, and the authors don't describe a rigorous methodology.
This will necessarily be a subjective judgement to some extent. See also above.
5.
We agree that we should rephrase and clarify and have changed the wording to (page 9, line 24-25):
6.
In contrast I am comfortable with the results relating to literature searching in trial protocols as this is less subjective and less prone to misclassification. However, one point of clarification should be made. If trials involved new medications or devices at an early stage of their development there may not be a substantial publication history and the relevant information may sit in sponsors' files. It's unlikely anyone will have done systematic reviews. I don't know how relevant it is here, but the authors might comment. This is indeed a relevant point of clarification, and we agree that this is important to mention. While it is less likely that relevant trials would exist for interventions at early stages of development it would still, in our opinion, be relevant to conduct searches, as similar interventions might exist that have been tested.
We added the following in the discussion (page 11, line (32-37) :
"Some of the protocols in our sample described trials involving medications or devices at an early stage of development and for such trials systematic reviews are unlikely to exist. However, a systematic search could still be relevant as similar interventions may have been tested. In 2006 six participants developed multiple organ failure after a phase one trial in the United Kingdom and it has been suggested that a systematic review of pre-clinical and clinical data could have predicted the lifethreatening adverse effects.17-18" 7.
In the Discussion the authors have again taken a very polar view of the ethics of rationales for trials. They cite two examplesa cumulative meta-analysis of streptokinase in AMI showing that after 1973 there was compelling evidence of benefit. I am not sure what point they are making but it is unreasonable to suggest that all thrombolytic trials post 1973 were 'unethical'. Ethical standards evolve with new knowledge and retrospective application of a 2018 standard is simply unfair and biased. In the case of their other example, aprotinin, the situation is much more complicated than they state. I have performed a systematic review of this literature. Small inadequately powered trials were done over a long period in different settingscardiac surgery, general surgery, orthopedic surgery, children etc. The difficulty with all these trials is that although they continued to show a reduction in blood loss (and sometimes need for reoperation) they were inconclusive about other major clinical outcomes. Eventually the authors of the systematic review cited in this manuscript performed a large RCT which showed an increase in mortality with aprotinin compared with lysine analogues. So, to claim it was unethical to do further trials at an earlier stage is misleading and what was needed was a proper trial. My point here, again, is that these issues are not black and white.
We have changed the paragraph and made it clear that we are of course not suggesting that all post 1973 trials were unethical, as systematic reviews and meta-analysis were not standard at the time. We are merely pointing out a case were many potentially superfluous trials were conducted which underlines the importance of examining the existing evidence before conducting a trial.
We added the following (page 11, line 7-9):
"As meta-analyses were not routinely used at this point in time, we should not judge this by modern standards. However, it highlights the importance of examining existing evidence before conducting a new trial."
Regarding aprotinin, we thank you for your clarification and have deleted the example.
8.
Finally, I support the authors' call for much more detailed literature reviews during the planning of trialsa point made by othersand I agree with their call for ethics review organisations to be fully transparent in their work as they are working in the public interest.
Thank you for this comment, and for the above. We are very happy with the detailed review and are sure that the final manuscript will be substantially strengthened by incorporating the review comments.
Other Points 9.
To start with Methods: The authors state "Our previous research on Danish trial protocols indicated that a sample size of 60 protocols would be sufficient to answer our research questions." I don't understand the scientific basis of this statement. As most of the paper is descriptive and concerned with proportions it would be usual to estimate the power of the study to detect certain proportions with a specified precision; alternatively, make no mention of sample size and provide confidence intervals for key statistics.
We agree and have deleted the statement.
10.
The authors have used the SPIRIT guidelines to assess the appropriateness of choice of comparators (controls). They reference the Statement itself, rather than the explanation and elaboration paper, published in the BMJ. I think the latter is more appropriate as it has a section on selection of comparators, which is useful but far from comprehensive and doesn't provide a framework that would cover the broad range of interventions used here (see below).
We agree and now cite both.
11.
Protocols were selected between October 2012 through March 2013 was that 1st to 31st? Actual dates should be provided.
Yes it was indeed between 1st October 2012 and 31st of March 2013 which has now been clarified.
12.
They state "We sought additional information about the research projects through clinicaltrials.gov, and the World Health Organisation International Clinical Trial Registry Platform. If we were unable to find a study in trial registries, we supplemented with a Google search." I can understand the information in registries but what were they looking for in a Google search? What terms did they search onwere they looking for the protocol or a subsequent publication of the trial?
The Google searches were supplemental to the trial registry searches, i.e. if we were unable to identify studies in the trial registries we tried to find more information about the trials using google searches. We were not looking for protocols or publications, only information that would enable us to determine whether studies were eligible. We have made this clearer in the manuscript by writing the following (page 6, line 1-11):
"The website of the ethics committees only contained information on the date of approval; the project title; the Danish region where the trial would take place; and the name of the coordinating investigator. We sought additional information (described below) about the research projects through clinicaltrials.gov, the EU Clinical Trials Register (EudraCT), and the World Health Organization International Clinical Trial Registry Platform using information from the website of the ethics committee (e.g. intervention or a trial identifier found in the project title). If we were unable to identify the eligible studies in trial registries, we attempted to identify a trial ID through Google searches using the information from the Committee's website. Trial characteristics from these registries were extracted and eligibility was assessed by one observer. We extracted information on the following characteristics: study type, design, population, interventions, inclusion and exclusion criteria of the trial, primary outcomes, and desired sample size. When there was uncertainty about eligibility, a second observer was consulted"
13.
Why were decisions made by only one observer? There are six named authors. Which of the authors extracted the information? Given the subjective nature of some steps why was this not done in duplicate?
The data extraction was immensely time consuming, and it was not feasible to have all extractions done by two observers. Although we cannot exclude that some information was lost due to oversight, we do not consider this a major problem because the transfer of all the information to Word and Excel was a rather straightforward process. In contrast, all judgements and decisions were made by more than one observer. We have made this clear now (page 6, line 20-28):
"As the protocols were long and contained much information irrelevant to our project one observer entered applicable text into a Word document. The introduction or background section as well as any sections of the protocol addressing ethical issues or clinical information on the used interventions were extracted this way. All subjective judgments based on the extracted texts were performed by two observers independently and all ambiguities or disagreements were discussed, if necessary involving a third observer.
Additionally, all trials where the choice of treatment and comparator could be questioned were discussed with a senior researcher. Our assessments were entered into a standardized data extraction sheet.
Any information in the protocols about the source of funding and the type of comparator used were also extracted from the protocol and entered into the data extraction sheet."
15.
"For the trials that might be eligible". I understand the main eligibility criteria, but what criteria were used by the single observer at this screening stage?
At this stage we only had access to relatively sparse information (from trial registries) about the trials. Therefore, we could not be entirely sure whether they fulfilled the eligibility criteria until we had the full protocol. Thus, the criteria were the same, but we did not always have enough information to judge whether they were met.
We have changed the paragraph to the following (page 6, line 12-16):
"For trials that we considered potentially eligible based on information from trial registries, we contacted the relevant regional ethics committee and requested copies of the protocols, informed consent forms, financial and publication agreements between the study sponsors and the investigators, and any other relevant information about the trials, e.g. the investigators brochure. We emphasised that the results would be published in a manner that would not allow identification of individual trials."
VERSION 2 -REVIEW
REVIEWER
David Henry Bond University, Australia REVIEW RETURNED 15-Apr-2019
GENERAL COMMENTS
I think the authors have done a good job in providing additional detail of their methods, and in toning down the language to better match their findings. The editing of the manuscript is quite extensive, and it reads as a more balanced piece and will be more useful as a result of that.
But, I have one main remaining concern about the Methods and Results. To explain this, I need to quote from the text of the revised paper.
Page 8 lines 2-5 'We did not judge the soundness of the scientific rationale for the trials as this would require content expertise, rather we judged whether a scientific rationale was provided and whether it was backed by references to systematic reviews or randomised trials.'
On page 7 lines 6 to 15 the authors state: 'Justification for choice of comparator' 'We noted whether the choice of comparator in the individual protocol was justified as recommended in the SPIRIT reporting guidelines.4,10 We distinguished between an explicit and an implicit justification. We defined that a protocol explicitly justified the choice of comparator when a specific reason for the choice was given, e.g. a section such as "Rationale for choice of comparator" or statements such as "Regarding justification of placebo: "Placebo is the appropriate comparator, since the approved therapies available in same countries are not routinely used for treatment of lower-risk disease."" The justification for choice of comparator was considered implicit when for example the control group was stated to simply receive the usual standard of care or when there was documented uncertainty about which of two active interventions was' Both paragraphs describe a reasonable process that depends on the judgments of the original authors of the study protocols.
But, on Page 7 lines 25 to 31 the authors write: 'We compared the references in the protocols with the results of a systematic search we performed ourselves…. We defined a comparator as potentially unjustified if another intervention had already been proven more effective for the outcomes measured and no compelling reason for using another comparator was provided. When judging comparative efficacy, we only considered direct evidence, i.e. we only judged a comparator potentially unjustified if another intervention had been directly tested against the comparator for the same (or a similar) indication and found superior.' In contrast to the previous paragraphs the authors are making quantitative judgments that rely on statistical inference and content knowledge. As I pointed out previously, they have not stated clear rules for doing this. This is important because choice of comparator goes to the heart of their continuing concern about the ethical basis of some trials. Although they have softened the language, they still imply (Discussion) that somehow the investigators of these trials might be in breach of the Helsinki Declaration. As I illustrated in my first review the 11 examples in the Text Box can be superficially rebuttedand they have not responded to this in sufficient detail. In my view they crossing a line in making these claims about the ethics of these trials. As I stated in the preamble to my earlier report, I think these claims should be deleted from the manuscript.
VERSION 2 -AUTHOR RESPONSE
Response to reviewers
We would like to thank the reviewer for his comments, and we agree that the editing done after the first round of peer review has improved the paper. We have tried to answer the points made by the reviewer one by one below:
The reviewer states that we have not made clear rules for our judgements about the justification for use of comparators, and that such judgements rely on statistical inference and content knowledge.
We acknowledge that we have not defined strict rules for our judgements of whether use of a comparator or a rationale was sufficiently justified. This is difficult to do for a project like ours, and we maintain that such judgements are inherently subjective. We have tried to clarify the criteria we used by restructuring the methods section. It is true that we do not have content area expertise for all the clinical areas included in the paper, but we would like to point out that we only suggest that the rationale for trials may be ethically problematic, not that we have demonstrated that this is the case.
Additionally, the ethical committee members will be in a similar or worse situation. They might have members with content area expertise for some trials but not for the majority. We believe it is a fundamental part of the ethical committees' job to determine whether trials use fair comparatorsboth for ethical and methodological reasonsand maintain that they must be able to make judgements about the ethical justification of a trial, despite the subjective nature of this judgement and even when there is no member of the committee with specific expertise within the medical specialty of a trial. Therefore, protocols need to justify clearly the choice of comparators and provide relevant evidence in support.
The reviewer points out that we imply that the investigators of these trials might be in breach of the Helsinki Declaration.
We agree that we suggest this but maintain that we only say that the trials identified might be in breach of the Helsinki Declaration. We agree completely with the reviewer that we cannot and should not draw firm conclusions about the ethical justification of a trial based on the information available in protocols. Therefore, we only say that, based on the information available in the protocol, it is not clear if the trial is ethically justified. We consider this an important difference and that the question about the ethical justification of trials is important to raise. This is, in our opinion, the equivalent of an ethical committee requesting more information. We have now clarified these points further in our manuscript.
The reviewer points out that we have not replied to his rebuttals of the examples in our Text Box.
We agree that for all the cases we have identified there could be circumstances that would make the trialists' choices ethically acceptable. However, we maintain that it is problematic that no such information was provided in the protocols, e.g. to justify the use of placebo where effective treatments were likely available.
The above points lead the reviewer to suggest that these claims are deleted from the manuscript.
We think it would weaken our manuscript and leave out important questions to delete these sections.
As we have outlined above, we believe our judgements are fair and reasonable, and we maintain that we should be allowed to point out that it was not possible to confirm that a number of trials were ethical based on the information available in the protocol.
We now make it clearer that we are not passing a judgement on the ethical justification of the individual trials. The changes are outlined below:
In the Methods section of our paper, we have moved the paragraphs describing our subjective judgements from the data extraction section to a new Analysis section. We have changed the wording:
"Analysis
We compared the references in the protocols with the results of our own systematic search.
We deemed a comparator questionable if:
-One or more previous randomised trials conducted with the same intervention, for the same condition, and using the same outcome had found that the intervention was superior to the proposed comparator and the choice was not further justified in the protocol.
We deemed the rationale for conducting a study questionable if a protocol did not provide any evidence of clinical equipoise to justify a RCT. We based this judgement on the principles outlined in item 6A of the SPIRIT statement4 and in the SPIRIT explanation and elaboration paper10 where it is explained that a protocol should "summarise the importance of the research question, justify the need of the trial in the context of available evidence, and present any available data regarding the potential effects of the interventions (benefits and harms)".4,10 Thus we examined if protocols:
-Identified a lack of studies of direct relevance, or -Established that results of previous studies were inconclusive.
We also considered whether the choice of outcomes and methodology (e.g. timing of treatment) was appropriate for the scientific question posed, based on the available evidence.
For both the justification of comparators and the scientific rationale for the research question, we did not judge whether a trial was unethical but examined whether the information presented would enable ethics committees to evaluate if the trials were justified.
For studies where we found insufficient information, we summarised the reasons in a tabular format. "
On page 10, line 1 we have removed "and ethical justification"
On page 10, lines 11-13 we have changed the paragraph to the following:
"We identified 11 protocols (16%) where the choice of treatment or comparator could be questioned given the evidence available at the time and the information provided in the protocols. The reasons for our judgements are described in Box 1."
On page 11, lines 7-13 we have changed the paragraph to the following:
"Sixteen percent of included trial protocols either did not present a rationale for conducting the study or used comparators that could be questioned based on the evidence available at the time and did not provide information to explain these choices. While these trials may be ethically acceptable, we were unable to confirm this based on the information available in the protocols. Thus, a considerable number of research participants could potentially have been exposed to suboptimal treatment or unnecessary inconvenience, discomfort, or risk of harm. "
On Page 12, lines 30-31 we have added the following under limitations:
"Finally, the reporting and reproducibility of our study is limited by the confidentiality agreements signed in order to obtain access to protocols."
We have changed the results section of the abstract to the following:
"Results Sixty-seven protocols were included. Only two (3%) of the protocols explicitly stated to have conducted a literature search and only one (1%) provided information that allowed the search to be replicated. Eleven (16%) of the protocols described trials where we found the information insufficient to judge if the trial was ethically justified, either due to a comparator that was not supported by the presented evidence (six protocols), because they did not present a rationale for conducting the trial (two protocols), or for both reasons (three protocols). For eight (12%) of the protocols, our search identified trials that could have been relevant to cite as justification."
VERSION 3 -REVIEW
REVIEWER
David Henry
Bond University, Gold Coast, Australia REVIEW RETURNED 22-Sep-2019 GENERAL COMMENTS I am happy with the revisions -they have been handled in a thoughtful manner and the manuscript is more balanced as a result. One very minor point. The convention is to refer to 'ethics committees' rather than 'ethical commitees'. This seems to be a UK/Commonwealth convention -other jurisdictions refer to 'Research Ethics Boards' or 'Institutional Review Boards'
